Telesis Bio

Telesis Bio Pre-Tax Margin

The Pre-Tax Profit Margin of Telesis Bio (TBIO) as of Oct 27, 2026 is -173.40 %. In the previous year, Pre-Tax Profit Margin was -176.59 % — a change of -1.81% (higher).

Pre-Tax Margin

-173.40 %

YoY

-1.81%

Last updated:

Pre-Tax Profit Margin of Telesis Bio is 2023 -173.40 % . Pre-Tax Profit Margin of Telesis Bio was 2022 -176.59 % . It decreases by -1.81% higher compared to the previous year.

The Telesis Bio Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-7,250.70 USD
Jan 1, 2019
-172.78 USD
Jan 1, 2020
-273.80 USD
Jan 1, 2021
-352.66 USD
Jan 1, 2022
-176.59 USD
Jan 1, 2023
-173.40 USD
The Telesis Bio Pre-Tax Margin history
YEARPre-Tax MarginYoY
-173.40 %-1.81%
-176.59 %-49.93%
-352.66 %+28.80%
-273.80 %+58.47%
-172.78 %-97.62%
-7,250.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Pre-Tax Profit Margin of Telesis Bio is -173.40 % in 2023.

Pre-Tax Profit Margin of Telesis Bio changed from -176.59 % to -173.40 %, representing a -1.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Telesis Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Telesis Bio

All Key Metrics — Telesis Bio